香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 （根據公司條例在香港註冊成立的有限責任公司） （股份代號：836） 海外監管公告 本海外監管公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 以下為華潤電力控股有限公司（「本公司」）就本公司全資附屬公司華潤電力投資有限 公司於2025年8月20日在北京金融資產交易所網站( https://www.cfae.cn )、中國貨幣 網( https://www.chinamoney.com.cn )、上海清算所網站( https://www.shclearing.com.cn ) 刊發的資料全文，僅供參閱。 承董事會命 華潤電力控股有限公司 主席 史寶峰 香港，2025年8月20日 於本公告發表日期，本公司的董事會包括三名執行董事，即史寶峰先生（主席）、 王波先生及宋葵先生；三名非執行董事，即周波先生、李傳吉先生及曾俊先生； 及六名獨立非執行董事，即梁愛詩女士、錢果豐博士、蘇澤光先生、楊玉川 ...

Core Viewpoint - The China Securities Hong Kong 300 Infrastructure Index (H300 Infrastructure) has shown positive performance, with a 2.81% increase over the past month, a 5.08% increase over the past three months, and an 11.50% increase year-to-date [2] Group 1: Index Performance - The H300 Infrastructure Index is currently reported at 1935.88 points [1] - The index reflects the overall performance of listed companies in various sectors such as banking, transportation, resources, infrastructure, logistics, and leisure [2] Group 2: Index Composition - The top ten weighted companies in the H300 Infrastructure Index are: China Mobile (33.75%), Cheung Kong (8.46%), CLP Holdings (8.25%), China Telecom (5.48%), Hong Kong and China Gas (4.88%), Power Assets Holdings (4.68%), China Unicom (3.86%), ENN Energy (3.12%), China Resources Power (2.53%), and CK Infrastructure Holdings (2.48%) [2] - The index is composed entirely of companies listed on the Hong Kong Stock Exchange, with a sector breakdown of 53.10% in telecommunications services, 41.42% in utilities, 4.22% in construction and decoration, and 1.27% in transportation [2] Group 3: Index Adjustment Mechanism - The index samples are adjusted biannually, with adjustments implemented on the next trading day following the second Friday of June and December [3] - Weight factors are generally fixed until the next scheduled adjustment, with special circumstances allowing for temporary adjustments [3]

Core Viewpoint - The Shanghai Municipal Government and China Resources (Group) Co., Ltd. signed a strategic cooperation agreement to enhance collaboration across multiple sectors, aiming for mutual benefits and high-quality development [1] Group 1: Strategic Cooperation - The agreement emphasizes leveraging Shanghai's technological innovation, industrial clustering, and business environment alongside China Resources' diverse industry strengths and expertise in state-owned capital investment [1] - The partnership will focus on cooperation in key areas such as integrated circuits, pharmaceuticals and healthcare, energy services, urban construction and operation, industrial finance, and technology and emerging industries [1] Group 2: Goals and Objectives - The collaboration aims to achieve complementary advantages between central and local governments, promoting high-quality development and integration [1] - The initiative supports China Resources in its goal to become a globally competitive world-class enterprise while assisting Shanghai in becoming a modern international metropolis with global influence [1]

Group 1 - China Resources Power recently held a bidding for 3GW photovoltaic module procurement, with average bid prices significantly higher than current market prices, indicating potential price increases in the industry [1] - The average bid prices for the three segments were 0.729 CNY/W, 0.729 CNY/W, and 0.718 CNY/W respectively, which are above the current average prices of 0.67 CNY/W for centralized projects and 0.69 CNY/W for distributed projects [1] - The expectation of a cancellation of export tax rebates for photovoltaic products may lead to further price increases for overseas components, supported by the upcoming 20GW component bidding by Huadian Group [1] Group 2 - Junda Co. has achieved large-scale production of N-type batteries and focuses on cost reduction and efficiency improvement, leading the industry in battery efficiency and cost [2] - JA Solar Technology is a leading company in photovoltaic modules, with a production capacity of 100GW, and its silicon wafer and battery capacities exceed 80% and 70% of its module capacity respectively [2]

Group 1 - The establishment of China Resources City Yu New Energy (Hua Yuan) Co., Ltd. has been registered with a capital of 131.493 million RMB [1] - The company's business scope includes wind power generation technology services, solar power generation technology services, biomass energy technology services, energy storage technology services, emerging energy technology research and development, and power generation technology services [1] - China Resources Power New Energy Investment Co., Ltd. holds a controlling stake of 51% in the newly established company [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 香港，2025年8月15日 （根據公司條例在香港註冊成立的有限責任公司） （股份代號：836） 海外監管公告 本海外監管公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 以下為華潤電力控股有限公司（「本公司」）就本公司全資附屬公司華潤電力投資有 限公司於2025年8月15日在深圳證券交易所網站(http://www.szse.cn)刊發的資料全 文，僅供參閱。 承董事會命 華潤電力控股有限公司 主席 史寶峰 於本公告發表日期，本公司的董事會包括三名執行董事，即史寶峰先生（主席）、 王波先生及宋葵先生；三名非執行董事，即周波先生、李傳吉先生及曾俊先生； 及六名獨立非執行董事，即梁愛詩女士、錢果豐博士、蘇澤光先生、楊玉川先 生、陳克勤先生及陳勇先生。 债券代码：148076.SZ 债券简称：22 华润 Y2 华润电力投资有限公司 2022 年面向专业投资者公开发行可续期公司债券 （第二期） ...

Group 1: Core Insights - Rongchang Biologics (09995.HK) announced that its innovative drug Taitasip (brand name: Tai Ai®) for treating primary Sjögren's syndrome has met the primary endpoint in a Phase III clinical trial in China [1] - Taitasip is the first BLyS/APRIL dual-target fusion protein drug to complete Phase III research in the field of Sjögren's syndrome globally [1] - The clinical trial was a multi-center, randomized, double-blind, placebo-controlled study aimed at evaluating the efficacy and safety of Taitasip, with the primary endpoint being the change in ESSDAI score at week 24 compared to baseline [1] Group 2: Disease Background and Drug Mechanism - Sjögren's syndrome is a chronic inflammatory autoimmune disease characterized by lymphocytic infiltration and damage to exocrine glands, leading to persistent dry mouth and dry eyes, and can affect multiple organ systems [2] - The prevalence of Sjögren's syndrome in China is estimated to be between 0.3% and 0.7%, with an increasing trend indicating a significant unmet clinical need [2] - Taitasip is a novel dual-target fusion protein developed by the company that simultaneously inhibits the overexpression of BLyS and APRIL, effectively preventing abnormal differentiation and maturation of B cells [2] Group 3: Regulatory and Clinical Recognition - Taitasip has received multiple authoritative guideline recommendations in China, including the "Clinical Practice Guidelines for Sjögren's Syndrome" and the "Expert Consensus on B-cell Targeted Therapy for Rheumatic and Immune Diseases" [2] - Internationally, Taitasip has been granted Fast Track designation by the U.S. FDA for its indication in Sjögren's syndrome and has been approved to conduct global multi-center Phase III clinical trials [2]

Core Viewpoint - China Resources Power Holdings Company Limited reported a significant increase in electricity sales for its subsidiaries in July 2025, driven by new capacity and high-temperature weather conditions [1] Group 1: Electricity Sales Performance - The total electricity sales volume for subsidiaries reached 20,975,595 MWh in July 2025, representing a year-on-year increase of 14.1% [1] - The subsidiary thermal power plants sold 16,331,696 MWh, marking a year-on-year increase of 17.2% [1] - The subsidiary wind power plants experienced a decrease in sales volume to 3,430,109 MWh, down 5.3% year-on-year due to reduced wind speeds in southern and central China [1] - The subsidiary solar power plants achieved sales of 1,028,427 MWh, reflecting a substantial year-on-year increase of 44.8% [1] Group 2: Cumulative Sales Data - For the first seven months of 2025, the cumulative electricity sales volume for subsidiaries reached approximately 123 million MWh, an increase of 5.4% year-on-year [1] - The cumulative sales from subsidiary thermal power plants amounted to 87,473,358 MWh, with a year-on-year increase of 1.6% [1] - The cumulative sales from subsidiary wind power plants reached 29,294,247 MWh, showing a year-on-year increase of 12.6% [1] - The cumulative sales from subsidiary solar power plants totaled 5,163,987 MWh, representing a year-on-year increase of 33.8% [1]

格隆汇8月14日丨华润电力(00836.HK)公告，2025年7月附属电厂售电量达到20,975,595兆瓦时，同比增 加了14.1%，其中，因新增装机投产及高温天气带动电力需求增加，附属火电厂售电量达16,331,696兆 瓦时，同比增加了17.2%；另外，高温天气导致华南、华中等地区风速下降，附属风电场售电量为 3,430,109兆瓦时，同比减少了5.3%；附属光伏电站售电量达1,028,427兆瓦时，同比增加了44.8%。 2025年首七个月附属电厂累计售电量达到122,955,546兆瓦时，同比增加了5.4%，其中，附属火电厂售 电量达87,473,358兆瓦时，同比增加了1.6%；附属风电场累计售电量达到29,294,247兆瓦时，同比增加 了12.6%；附属光伏电站累计售电量达到5,163,987兆瓦时，同比增加了33.8%。 ...

Core Viewpoint - China Resources Power (00836) reported a significant increase in electricity sales for its subsidiaries in July 2025, driven by new capacity and high-temperature weather conditions [1] Group 1: Electricity Sales Performance - In July 2025, total electricity sales reached 20,975,595 MWh, a year-on-year increase of 14.1% [1] - The subsidiary thermal power plants sold 16,331,696 MWh, marking a 17.2% increase year-on-year [1] - Wind power sales decreased to 3,430,109 MWh, down 5.3% year-on-year due to reduced wind speeds in southern and central China [1] - Solar power sales surged to 1,028,427 MWh, reflecting a 44.8% year-on-year increase [1] Group 2: Cumulative Sales Data - For the first seven months of 2025, cumulative electricity sales reached approximately 123 million MWh, a 5.4% increase year-on-year [1] - Thermal power plants contributed 87,473,358 MWh, with a year-on-year increase of 1.6% [1] - Cumulative wind power sales amounted to 29,294,247 MWh, up 12.6% year-on-year [1] - Solar power plants recorded cumulative sales of 5,163,987 MWh, representing a 33.8% year-on-year increase [1]